pat2-k3 Antibody

What detection methods are compatible with PAT2 antibodies?

PAT2 antibodies, such as the mouse monoclonal IgM antibody (F-3), have been validated for multiple detection methods in laboratory research. These include:

• Western blotting (WB): For detecting denatured PAT2 protein in tissue or cell lysates

• Immunoprecipitation (IP): For isolating PAT2 protein complexes from cellular extracts

• Immunofluorescence (IF): For visualizing PAT2 localization within cells and tissues

• Enzyme-linked immunosorbent assay (ELISA): For quantitative detection of PAT2

When designing experiments, researchers should consider that optimal antibody dilutions and incubation conditions may vary between these methods. Validation controls should be included to confirm specificity, particularly when working with new tissue types or experimental conditions.

How does PAT2 antibody cross-reactivity influence experimental design?

When designing experiments with PAT2 antibodies, understanding cross-reactivity across species is critical for accurate interpretation of results. The PAT2 antibody (F-3) has demonstrated reactivity with PAT2 of mouse, rat, and human origin . This cross-species reactivity provides advantages for comparative studies and translational research.

When planning experiments:

• Validate the antibody in your specific model system before conducting critical experiments

• Include appropriate positive and negative controls from different species when available

• Consider potential cross-reactivity with related protein family members, particularly when working in tissues with complex protein expression profiles

• Document the specific clone and manufacturer of the antibody used in your methods to ensure reproducibility

How can humanized antibodies against PAT2 be developed and validated?

Developing humanized antibodies against targets like PAT2 involves sophisticated techniques to maintain binding affinity while reducing immunogenicity. The process typically follows these methodological steps:

• Initial sequence analysis: Computational methods are used to predict the most human-like sequence for antibody humanization. Tools like CamSol can study the expected solubility of resulting trajectories and refine potential candidates .

• Combinatorial testing: Different humanized heavy and light chain combinations must be tested systematically. For example, in humanization processes similar to those used for other antibodies, multiple heavy chains (H1, H3, H5, H6) can be combined with different light chains (K1, K3, K5, K6, K7, K8) using high-throughput microscale production systems .

• Binding affinity validation: ELISA assays are critical for testing binding ability of humanized antibodies to their target. The supernatants with highest binding ability should be purified and tested at scalar dilutions (e.g., 1:2 dilutions starting from 5 μg/ml) to identify optimal heavy:light chain combinations .

• Comparative analysis with parent antibody: IC50 values and binding kinetics should be evaluated to compare humanized versions with the original murine antibody. Competitive ELISA can be used to determine Kd values (typically in the range of 10^-10 M for high-affinity antibodies) .

• Specificity testing: Cross-reactivity with structurally related proteins should be assessed to ensure target specificity .

What strategies can overcome inconsistent results in PAT2 antibody-based experiments?

When facing inconsistent results in PAT2 antibody experiments, a systematic troubleshooting approach is recommended:

• Antibody validation assessment:

  • Confirm antibody specificity using knockout/knockdown controls

  • Test multiple antibody lots if available

  • Verify antibody functionality using positive control samples

• Protocol optimization:

  • Titrate antibody concentrations systematically

  • Optimize incubation times and temperatures

  • Adjust blocking conditions to reduce background

• Sample preparation considerations:

  • Evaluate different tissue/cell lysis methods

  • Consider the effect of fixation methods on epitope accessibility

  • Test fresh versus frozen samples for potential differences

• Data analysis refinement:

  • Use quantitative methods with appropriate normalization

  • Apply statistical tests appropriate for your sample size

  • Consider blinded analysis to reduce unconscious bias

• Controls implementation:

  • Include technical and biological replicates

  • Use appropriate positive and negative controls

  • Consider isotype controls for immunoassays

How does PAT2 structure influence antibody binding kinetics?

The structural features of PAT2 significantly impact antibody binding kinetics and should inform experimental design. PAT2, like other members of the proton-coupled amino acid transporter family, is characterized by the presence of three conserved histidine residues, with His-55 being particularly critical for catalytic activity . This structural characteristic has important implications for antibody binding:

• Epitope accessibility: The transmembrane nature of PAT2 means that certain epitopes may only be accessible under specific conditions or detergent treatments.

• Conformational states: Like other transporters, PAT2 likely undergoes conformational changes during its transport cycle. Antibodies may have different affinities for different conformational states of the protein, similar to how antibodies against P2X3 receptors show distinct functional effects depending on the kinetic state of the channel .

• Binding kinetics considerations: When studying PAT2 with antibodies, researchers should consider:

  • On/off rates that may vary with buffer conditions

  • Temperature dependence of binding

  • Effects of pH on binding, particularly important for proton-coupled transporters

  • Potential allosteric effects of antibody binding on transporter function

What are the optimal protocols for using PAT2 antibodies in immunofluorescence studies?

For optimal immunofluorescence studies using PAT2 antibodies, the following methodological approach is recommended:

• Sample preparation:

  • For cultured cells: Grow cells on coverslips and fix with 4% paraformaldehyde (10-15 minutes at room temperature)

  • For tissue sections: Use freshly prepared 10-12 μm cryosections or paraffin sections with appropriate antigen retrieval

• Permeabilization and blocking:

  • Permeabilize with 0.1-0.3% Triton X-100 for 10 minutes

  • Block with 5-10% normal serum (species different from antibody source) with 1% BSA for 1 hour at room temperature

• Primary antibody incubation:

  • Dilute PAT2 antibody appropriately (typically 1:50-1:200 range for IF applications)

  • Incubate overnight at 4°C in a humidified chamber

  • For co-localization studies, combine with antibodies against neuronal markers given PAT2's high expression in neural tissues

• Secondary antibody application:

  • Use appropriate fluorophore-conjugated secondary antibodies specific to the host species of PAT2 antibody

  • Incubate for 1-2 hours at room temperature protected from light

  • Include DAPI or other nuclear counterstains

• Controls and validation:

  • Include secondary-only controls to assess background

  • Use tissues known to be positive or negative for PAT2 expression

  • Consider competition assays with PAT2 peptides to confirm specificity

• Imaging considerations:

  • Use confocal microscopy for subcellular localization studies

  • Acquire z-stacks for analyzing distribution throughout the cell volume

  • Employ consistent exposure settings across experimental and control samples

How can PAT2 antibodies be effectively used in co-immunoprecipitation experiments?

To effectively use PAT2 antibodies in co-immunoprecipitation (co-IP) experiments to identify protein interaction partners, follow this methodological approach:

• Lysate preparation:

  • Harvest cells expressing PAT2 (e.g., neural tissues, transfected cell lines)

  • Lyse cells in a non-denaturing buffer containing:

    • 50 mM Tris-HCl (pH 7.4)

    • 150 mM NaCl

    • 1% NP-40 or similar mild detergent

    • Protease inhibitor cocktail

    • Phosphatase inhibitors (if phosphorylation states are relevant)

  • Clear lysate by centrifugation (14,000 × g for 15 minutes at 4°C)

• Pre-clearing step:

  • Incubate lysate with protein A/G beads for 1 hour at 4°C

  • Remove beads by centrifugation to reduce non-specific binding

• Immunoprecipitation:

  • Add PAT2 antibody to pre-cleared lysate (2-5 μg per 500 μg total protein)

  • Incubate overnight at 4°C with gentle rotation

  • Add fresh protein A/G beads and incubate for 2-3 hours at 4°C

  • Collect immunocomplexes by centrifugation and wash 4-5 times with lysis buffer

• Elution and analysis:

  • Elute bound proteins with SDS-PAGE sample buffer by heating at 95°C for 5 minutes

  • Analyze by SDS-PAGE followed by western blotting or mass spectrometry

• Controls for validation:

  • Include isotype control antibody IP

  • Consider reverse co-IP with antibodies against suspected interaction partners

  • Include input sample (10% of starting material) for reference

• Special considerations for membrane proteins:

  • PAT2 is a membrane protein, so optimize detergent concentration to maintain native protein interactions

  • Consider crosslinking approaches for transient interactions

  • For membrane proteins, 1% digitonin or 0.5-1% CHAPS may better preserve interactions than stronger detergents

What quantitative assays can accurately measure PAT2 function using antibody-based approaches?

To accurately measure PAT2 function using antibody-based approaches, researchers can implement these quantitative assays:

• Antibody-based transport inhibition assays:

  • Prepare cell models expressing PAT2 (either endogenous or transfected)

  • Pre-incubate cells with PAT2 antibodies at varying concentrations

  • Measure transport of radiolabeled or fluorescently labeled amino acid substrates

  • Calculate IC50 values to quantify inhibitory potency

  • Similar approaches have been used for other transporters, as demonstrated with P2X receptors where antibodies showed an estimated IC50 of 16 nM after short-term exposure

• Surface expression quantification:

  • Use cell-surface biotinylation followed by PAT2 antibody immunoprecipitation

  • Quantify surface versus total PAT2 protein levels

  • Monitor antibody-induced internalization effects on PAT2, similar to the profound inhibition observed with P2X3 after extended antibody exposure

• Calcium flux assays:

  • If PAT2 activity affects downstream calcium signaling

  • Prepare cells in multi-well format with calcium-sensitive dyes

  • Add antibodies at defined concentrations (e.g., 1 μM final concentration)

  • Monitor fluorescence changes using plate readers (settings: excitation ~485 nm, emission ~538 nm)

  • Quantify response curves and calculate EC50/IC50 values

• Electrophysiological measurements:

  • For functional characterization where transport activity generates measurable currents

  • Use patch-clamp techniques (automated systems like QPatch HT or conventional EPC 10 setup)

  • Apply antibodies at defined concentrations and times

  • Record current changes to assess direct functional effects of antibody binding

• ELISA-based internalization assays:

  • Develop dual-epitope assays using different antibodies

  • Quantify surface and internalized receptor pools after antibody treatment

  • Calculate internalization rates and steady-state distribution ratios

How does PAT2 antibody performance compare to antibodies targeting other transporter proteins?

When comparing PAT2 antibody performance to antibodies targeting other transporter proteins, several key performance metrics should be considered:

• Specificity profiles:

  • PAT2 antibodies should be evaluated for cross-reactivity with other PAT family members

  • Compared to antibodies against P2X receptors, which can distinguish between homomeric and heteromeric configurations

  • Validation through knockout/knockdown controls is essential for all transporter antibodies

• Functional modulation capabilities:

  • Some antibodies show state-dependent binding, as seen with P2X3 receptor antibodies that bind preferentially to the inactivated state

  • PAT2 antibodies should be assessed for their ability to modulate transport function

  • Comparable metrics include:

    • IC50 values (P2X3 antibodies have shown IC50 values around 16 nM)

    • Duration of effect (short-term vs. long-term exposure)

    • Mechanism of inhibition (direct blockade vs. induced internalization)

• Species cross-reactivity:

  • PAT2 antibody (F-3) detects PAT2 across mouse, rat, and human samples

  • This cross-species reactivity should be compared to antibodies against other transporters

  • Broader species reactivity generally indicates recognition of conserved epitopes

• Application versatility:

  • PAT2 antibodies have demonstrated utility in multiple applications (WB, IP, IF, ELISA)

  • This versatility should be benchmarked against other transporter antibodies

  • Performance in complex matrices (tissue lysates vs. recombinant proteins) is a key comparison point

• Stability and shelf-life:

  • Antibody stability under various storage conditions

  • Retention of activity after multiple freeze-thaw cycles

  • Lot-to-lot consistency in binding properties

What bioinformatic resources can help analyze PAT2 antibody binding sites across species?

For researchers investigating PAT2 antibody binding sites across species, several bioinformatic resources and methodological approaches are valuable:

• Sequence databases and alignment tools:

  • Use PLAbDab (Patent and Literature Antibody Database) which contains over 150,000 paired antibody sequences and 3D structural models

  • Apply sequence alignment tools (MUSCLE, Clustal Omega) to compare PAT2 sequences across species

  • Identify conserved regions that may serve as cross-species epitopes

• Epitope prediction algorithms:

  • BepiPred, DiscoTope, and EPCES can predict linear and conformational epitopes

  • Apply these tools to PAT2 sequences to identify likely antibody binding sites

  • Compare predicted epitopes with experimentally determined binding regions

• Structural analysis approaches:

  • Use homology modeling to predict PAT2 structure if crystallographic data is unavailable

  • Apply molecular docking simulations between antibody variable regions and PAT2

  • PLAbDab provides 3D structural models that can be used for comparative analysis

• Cross-reactivity prediction:

  • KA-search algorithm (available through PLAbDab) allows for rapid sequence identity searches

  • Identify potential off-target binding by comparing epitope regions across protein families

  • Filter results by applying sequence identity thresholds (e.g., >90% for both VH and VL regions)

• Functional annotation databases:

  • UniProt for detailed protein annotations across species

  • KEGG and Reactome for pathway analysis

  • These resources help contextualize antibody binding sites within functional domains

What are the key technical differences between mono-specific and cross-reactive PAT2 antibodies?

Understanding the technical differences between mono-specific and cross-reactive PAT2 antibodies is crucial for optimal experimental design:

• Epitope characteristics:

  • Mono-specific antibodies: Target variable regions unique to PAT2

  • Cross-reactive antibodies: Recognize conserved epitopes shared across PAT family members

  • The PAT family is characterized by three conserved histidine residues, with His-55 being critical for catalytic activity

• Validation requirements:

  • Mono-specific antibodies: Require validation in single-expression systems

  • Cross-reactive antibodies: Need comprehensive testing against all potential targets

  • Validation matrix:

  Antibody Type	Knockout Controls	Peptide Competition	Cross-Reactivity Testing
  Mono-specific	Essential	Recommended	Against similar proteins
  Cross-reactive	Limited utility	May not distinguish	Across target family

• Application-specific considerations:

  • Western blotting: Cross-reactive antibodies may detect multiple bands requiring careful interpretation

  • Immunohistochemistry: Mono-specific antibodies provide cleaner signal in complex tissues

  • IP applications: Cross-reactive antibodies may pull down multiple family members

• Experimental design implications:

  • Blocking peptide controls are more informative with mono-specific antibodies

  • Cross-reactive antibodies may be advantageous for comparative studies across species

  • For functional studies, mono-specific antibodies provide clearer mechanistic insights

• Production and humanization challenges:

  • Maintaining specificity during humanization processes requires careful CDR preservation

  • For therapeutic development, mono-specific humanized antibodies generally have better safety profiles

  • Humanization approaches should consider both CDR and framework regions to maintain specificity

How can PAT2 antibodies be employed in neurological disease models?

PAT2 antibodies offer significant potential for neurological disease research due to PAT2's high expression in the spinal cord and brain, where it influences neurotransmitter synthesis and neuronal function . Methodological approaches include:

• Expression profiling in disease models:

  • Compare PAT2 expression levels in healthy vs. diseased tissues using quantitative immunohistochemistry

  • Develop tissue microarrays for high-throughput screening across multiple patient samples

  • Correlate expression patterns with clinical parameters and disease progression

• Functional intervention studies:

  • Use antibodies to modulate PAT2 activity in neural cells

  • Similar to approaches used with P2X3 receptor antibodies, which demonstrated efficacy in pain models

  • Study effects on:

    • Neurotransmitter synthesis and release

    • Neuronal excitability

    • Synaptic plasticity

    • Circuit-level function

• Mechanistic investigation protocols:

  • Co-localization studies with markers of specific neuronal subtypes

  • Activity-dependent changes in PAT2 localization using antibody labeling

  • Isolation of PAT2-containing protein complexes from brain tissue

• In vivo applications:

  • Intracerebroventricular delivery of function-blocking PAT2 antibodies

  • Assessment of behavioral outcomes in rodent models

  • PET imaging with radiolabeled antibodies for non-invasive assessment

• Drug discovery platforms:

  • Use of PAT2 antibodies in high-content screening assays

  • Development of proximity-based assays (AlphaScreen, HTRF) using PAT2 antibodies

  • Creation of PAT2 biosensors incorporating antibody-derived binding domains

What are best practices for validating PAT2 antibodies in tissue microarrays?

For robust validation of PAT2 antibodies in tissue microarray (TMA) applications, researchers should follow these methodological best practices:

• Initial antibody characterization:

  • Determine optimal dilution ranges using positive control tissues known to express PAT2

  • Compare multiple PAT2 antibodies recognizing different epitopes when available

  • Validate specificity using blocking peptides, knockdown tissues, or recombinant protein controls

• TMA construction considerations:

  • Include representation of tissues with known PAT2 expression levels (brain, spinal cord)

  • Incorporate negative control tissues with minimal PAT2 expression

  • Use replicate cores (minimum 2-3) from each donor tissue

  • Include orientation markers and control tissue spots

• Staining protocol optimization:

  • Test multiple antigen retrieval methods (heat-induced vs. enzymatic)

  • Compare detection systems (polymer-based vs. avidin-biotin)

  • Determine optimal primary antibody incubation conditions (time, temperature, diluent)

  • Include isotype controls at matching concentrations

• Scoring and analysis methodology:

  • Develop standardized scoring criteria for PAT2 staining intensity and distribution

  • Use digital pathology tools for quantitative assessment

  • Implement multi-observer scoring to ensure reproducibility

  • Calculate inter- and intra-observer variability metrics

• Quality control measures:

  • Run positive and negative controls with each TMA batch

  • Periodically revalidate antibody performance with fresh lot testing

  • Document all procedural details for reproducibility

  • Confirm key findings with orthogonal detection methods

How do antibody-dependent modulation effects on PAT2 compare with small molecule approaches?

When comparing antibody-dependent modulation of PAT2 with small molecule approaches, several methodological considerations emerge:

• Mechanism of action differences:

  • Antibodies: Can induce receptor internalization through prolonged exposure, as demonstrated with P2X3 receptors where extended exposure (∼20 h) resulted in profound inhibition through antibody-induced internalization

  • Small molecules: Typically act through direct binding to functional domains or allosteric sites

  • Comparative analysis should include time-course studies to distinguish immediate vs. delayed effects

• Specificity profiles:

  • Antibodies: Generally offer higher target specificity with fewer off-target effects

  • Small molecules: May interact with multiple related transporters

  • Experimental design should include comprehensive selectivity testing:

  Modulator Type	Target Selectivity	Off-Target Testing	Duration of Effect
  Antibodies	High	Family members	Hours to days
  Small molecules	Variable	Broad panels	Minutes to hours

• Experimental approaches for comparison:

  • Functional transport assays measuring substrate uptake

  • Surface expression quantification using biotinylation

  • Electrophysiological recordings for real-time activity assessment

  • Calcium flux assays for downstream signaling effects

• Advantages and limitations assessment:

  • Antibodies: Limited blood-brain barrier penetration but longer duration of action

  • Small molecules: Better tissue penetration but potential metabolic instability

  • Combination approaches may provide synergistic effects worth investigating

• Translation to in vivo models:

  • Pharmacokinetic/pharmacodynamic studies comparing biodistribution

  • Different administration routes may be required (intrathecal for CNS targeting)

  • Assessment in disease models, similar to antibody testing in visceral pain models

How can computational approaches enhance PAT2 antibody design and application?

Computational approaches are increasingly valuable for enhancing PAT2 antibody design and applications. Methodological strategies include:

• Sequence-based antibody optimization:

  • Utilize database resources like PLAbDab that contain over 150,000 paired antibody sequences

  • Apply MG-score algorithms to identify human-like variable-region sequences for humanization

  • Use CamSol to study expected solubility of antibody sequences and refine selection of candidates

• Structure-based epitope mapping:

  • Generate 3D structural models of PAT2 using homology modeling

  • Perform molecular docking simulations to identify optimal binding epitopes

  • Use PLAbDab's structural models for comparative analysis with similar antibodies

• Machine learning applications:

  • Develop predictive models for antibody binding affinity

  • Train algorithms to identify optimal complementarity-determining regions (CDRs)

  • Use sequence-based predictions to identify antibodies with similar functional properties:

    • KA-search algorithm for rapid sequence identity searches

    • Structural similarity searches to identify functionally related antibodies

• Humanization strategies:

  • Apply computational protocols that identify the most human-like sequence

  • Generate multiple trajectories using different CDR definitions (e.g., IMGT, Kabat)

  • Combine computational predictions with experimental validation via ELISA binding assays

• Antibody engineering platforms:

  • In silico affinity maturation to enhance binding properties

  • Fc engineering for desired effector functions

  • Bispecific antibody design to simultaneously target PAT2 and related signaling molecules

What novel imaging techniques can leverage PAT2 antibodies for in vivo applications?

Emerging imaging techniques that can leverage PAT2 antibodies for in vivo applications offer new possibilities for neurobiological research:

• Antibody-based PET imaging:

  • Radiolabeling PAT2 antibodies with positron emitters (89Zr, 64Cu, 124I)

  • Optimizing radiochemistry for blood-brain barrier penetration

  • Quantitative assessment of PAT2 distribution in neurological disorders

• Optical imaging approaches:

  • Near-infrared fluorescence (NIRF) labeled antibodies for deeper tissue penetration

  • Antibody-based photoacoustic imaging for enhanced spatial resolution

  • Methodological considerations for antibody conjugation to preserve binding properties

• Multimodal imaging strategies:

  • Dual-labeled antibodies combining PET and optical reporters

  • Nanoparticle-antibody conjugates for MRI and fluorescence imaging

  • Implementation protocols for quantitative co-registration of multiple imaging modalities

• Advanced microscopy applications:

  • Super-resolution techniques (STORM, PALM) with directly labeled PAT2 antibodies

  • Expansion microscopy protocols optimized for antibody retention

  • Correlative light and electron microscopy (CLEM) for ultrastructural localization

• Functional imaging approaches:

  • Antibody-based biosensors reporting PAT2 conformational changes

  • Activity-dependent labeling strategies to visualize active transporters

  • Integration with electrophysiological recordings for multiparameter assessment

How might PAT2 antibodies be integrated into high-throughput screening platforms?

Integration of PAT2 antibodies into high-throughput screening (HTS) platforms offers opportunities for drug discovery and functional characterization. Methodological approaches include:

• Antibody-based competition assays:

  • Develop fluorescence polarization assays using labeled PAT2 antibodies

  • Screen compound libraries for molecules that displace antibody binding

  • Optimize protocol parameters:

    • Antibody concentration (optimally near Kd value)

    • Fluorophore selection for signal-to-noise optimization

    • Incubation time and temperature conditions

• Cell-based functional screening:

  • Generate stable cell lines expressing PAT2

  • Develop calcium flux assays similar to those used for P2X receptors

  • Create assay protocols with the following components:

    • Cell density optimization (typically 10,000-20,000 cells/well)

    • Calcium-sensitive dye selection (e.g., Calcium3 dye)

    • Standardized plate reader settings (excitation ~485 nm, emission ~538 nm)

    • Automated compound addition and kinetic reading parameters

• Automated microscopy platforms:

  • Implement high-content screening with PAT2 antibody-based readouts

  • Quantify PAT2 internalization in response to compound treatment

  • Analyze subcellular distribution changes using image analysis algorithms

• Antibody-based proximity assays:

  • Develop TR-FRET or HTRF assays using PAT2 antibody pairs

  • Design AlphaScreen approaches for PAT2 protein interactions

  • Establish multiplexed assay formats for simultaneous measurement of:

    • Surface expression levels

    • Protein-protein interactions

    • Transport activity

• Miniaturized biochemical assays:

  • Microfluidic platforms for antibody-based PAT2 detection

  • Label-free detection systems (SPR, BLI) for direct binding measurements

  • Droplet-based screening approaches for ultra-high-throughput applications